ERBB2 and breast carcinoma: In addition, a 2012 report from Seyhan et al. [39], implicated a number of ZNFs in modulating response to neratinib, a TKI of the ERBB family, in SKBR-3, a breast cancer cell line overexpressing ERBB2.